These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35581560)

  • 1. The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs.
    Moreira RDS; Costa EG; Dos Santos LFR; Miranda LHL; de Oliveira RR; Romão RF; Cozer RF; Guedes SC
    BMC Infect Dis; 2022 May; 22(1):473. PubMed ID: 35581560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in the pattern of COVID-19 hospitalizations and deaths after substantial vaccination of the elderly in Manaus, Amazonas State, Brazil].
    Orellana JDY; Cunha GMD; Marrero L; Leite IDC; Domingues CMAS; Horta BL
    Cad Saude Publica; 2022; 38(5):PT192321. PubMed ID: 35584432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVID-19 pandemic in Brazil: space-time approach of cases, deaths, and vaccination coverage (February 2020 - April 2024).
    Berra TZ; Alves YM; Popolin MAP; da Costa FBP; Tavares RBV; Tártaro AF; Moura HSD; Ferezin LP; de Campos MCT; Ribeiro NM; Teibo TKA; Rosa RJ; Arcêncio RA
    BMC Infect Dis; 2024 Jul; 24(1):704. PubMed ID: 39026177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hindrances to perform the COVID-19 vaccination in Brazil.
    Boschiero MN; Palamim CVC; Marson FAL
    Hum Vaccin Immunother; 2021 Nov; 17(11):3989-4004. PubMed ID: 34353218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
    Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covid-19: temporal evolution and immunization in the three epidemiological waves, Brazil, 2020-2022.
    Moura EC; Cortez-Escalante J; Cavalcante FV; Barreto ICHC; Sanchez MN; Santos LMP
    Rev Saude Publica; 2022; 56():105. PubMed ID: 36515307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Siqueira PG; Duarte HO; Moura MDC
    Vaccine; 2022 Jun; 40(28):3851-3860. PubMed ID: 35610105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends and spatial clusters of high risk for maternal death due to COVID-19 pre and during COVID-19 vaccination in Brazil: a national population-based ecological study.
    Siqueira TS; Silva JRS; Silva IMO; Menezes DR; Santos PE; Gurgel RQ; Martins-Filho PR; Santos VS
    Public Health; 2024 Jun; 231():15-22. PubMed ID: 38593681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Priority Settings at the Start of COVID-19 Mass Vaccination on Subsequent Vaccine Uptake in Japan: One-Year Prospective Cohort Study.
    Hori D; Takahashi T; Ozaki A; Tabuchi T
    JMIR Public Health Surveill; 2023 Jul; 9():e42143. PubMed ID: 37235691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Monteiro HS; Lima Neto AS; Kahn R; Sousa GS; Carmona HA; Andrade JS; Castro MC
    Vaccine; 2023 Sep; 41(39):5742-5751. PubMed ID: 37573202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial clustering of low rates of COVID-19 vaccination among children and adolescents and their relationship with social determinants of health in Brazil: a nationwide population-based ecological study.
    Santos VS; Siqueira TS; Silva JRS; Gurgel RQ
    Public Health; 2023 Jan; 214():38-41. PubMed ID: 36470038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
    Farias JP; da Silva PS; Fogaça MMC; Santana IVR; Luiz WB; Birbrair A; Amorim JH
    J Virol; 2022 Apr; 96(8):e0017722. PubMed ID: 35389263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
    Hitchings MDT; Ranzani OT; Lind ML; Dorion M; D'Agostini TL; de Paula RC; de Paula OFP; de Moura Villela EF; Scaramuzzini Torres MS; de Oliveira SB; Schulz W; Almiron M; Said R; de Oliveira RD; Vieira da Silva P; de Araújo WN; Gorinchteyn JC; Dean NE; Andrews JR; Cummings DAT; Ko AI; Croda J
    BMJ; 2022 Jun; 377():e070102. PubMed ID: 35697361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.